VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $45,908.30 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 2,749 shares of the company’s stock in a transaction dated Thursday, July 16th. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30. Following the completion of the sale, the insider owned 3,549,961 shares in the company, valued at approximately $59,284,348.70. This trade represents a 0.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Performance

Shares of VanEck Biotech ETF stock traded up $2.26 during midday trading on Thursday, hitting $206.25. The company had a trading volume of 3,431 shares, compared to its average volume of 6,008. The company has a 50 day moving average of $192.26 and a 200 day moving average of $191.76. VanEck Biotech ETF has a 52-week low of $154.75 and a 52-week high of $212.54.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of institutional investors have recently modified their holdings of the stock. Segall Bryant & Hamill LLC bought a new position in shares of VanEck Biotech ETF during the first quarter valued at $881,000. Paragon Private Wealth Management LLC raised its position in shares of VanEck Biotech ETF by 5.3% in the 1st quarter. Paragon Private Wealth Management LLC now owns 15,368 shares of the company’s stock worth $2,890,000 after purchasing an additional 775 shares during the last quarter. Bank of America Corp DE boosted its stake in VanEck Biotech ETF by 44.3% in the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after purchasing an additional 20,375 shares in the last quarter. Royal Bank of Canada boosted its stake in VanEck Biotech ETF by 4.3% in the 1st quarter. Royal Bank of Canada now owns 13,843 shares of the company’s stock worth $2,603,000 after purchasing an additional 565 shares in the last quarter. Finally, Wealthfront Advisers LLC grew its position in VanEck Biotech ETF by 27.0% during the 1st quarter. Wealthfront Advisers LLC now owns 7,004 shares of the company’s stock valued at $1,317,000 after purchasing an additional 1,491 shares during the last quarter. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.